Taiwania Capital, a private equity firm, led a $55m Series E funding round in Fractyl, a developer of medical device solutions for chronic diseases. The round had participation from investors Bessemer Venture Partners, General Catalyst, Domain Associates, Mithril Capital Management, Emergent Medical Partners, True Ventures, Catalio Capital Management, CDIB Venture Capital and YJ Capital. “Fractyl's founding mission was to find a better way to treat type 2 diabetes by addressing the root cause of disease that can reverse the disease process rather than manage its symptoms. We now have data from hundreds of patients with type 2 diabetes showing the durable benefits of a single Revita treatment. We welcome our new investors and the continued support of our returning investors, who recognize that we are at a pivotal moment in fundamentally redefining the treatment paradigm for metabolic diseases, including type 2 diabetes and NAFLD/NASH. We look forward to initiating our pivotal U.S. clinical trial later this year," Harith Rajagopalan, Fractyl Co-Founder and CEO.